Cargando…
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. ME...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462709/ https://www.ncbi.nlm.nih.gov/pubmed/36083883 http://dx.doi.org/10.1371/journal.pone.0273323 |
_version_ | 1784787248068165632 |
---|---|
author | Huhn, Gregory Poorbaugh, Josh Zhang, Lin Beasley, Stephanie Nirula, Ajay Brothers, Jennifer Welbel, Sharon Wilson, James Gillani, Sheena Weber, Kathleen M. Morack, Ralph Keckler, Kody Benschop, Robert J. |
author_facet | Huhn, Gregory Poorbaugh, Josh Zhang, Lin Beasley, Stephanie Nirula, Ajay Brothers, Jennifer Welbel, Sharon Wilson, James Gillani, Sheena Weber, Kathleen M. Morack, Ralph Keckler, Kody Benschop, Robert J. |
author_sort | Huhn, Gregory |
collection | PubMed |
description | BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. METHODS: Cook County Health employees provided blood samples and completed an online survey 8–10 weeks after a PCR-confirmed positive SARS-CoV-2 test (pre-vaccinated, N = 41) and again, 1–4 weeks after completion of a 2-dose series mRNA BNT162b2 COVID-19 vaccine (post-vaccinated, N = 27). Associations were evaluated between SARS-CoV-2 antibody titers, participant demographics, and clinical characteristics. Antibody titers and angiotensin-converting enzyme 2 (ACE2) neutralization were compared before and after the mRNA BNT162b2 COVID-19 vaccine. RESULTS: Antibody titers to the spike protein (ST4), receptor binding domain (RBD), and RBD mutant D614G were significantly associated with anosmia and ageusia, cough, and fever. Spike protein antibody titers and ACE2 neutralization were significantly higher in participants that presented with these symptoms. Antibody titers to the spike protein N-terminal domain (NTD), RBD, and ST4, and ACE2 IC50 were significantly higher in all post-vaccinated participant samples compared to pre-vaccinated participant sample, and not dependent on previously reported symptoms. CONCLUSIONS: Spike protein antibody titers and ACE2 neutralization are associated with the presentation of anosmia and ageusia, cough, and fever after SARS-CoV-2 infection. Symptom response to previous SARS-CoV-2 infection did not influence the antibody response from subsequent vaccination. These results suggest a relationship between infection severity and the magnitude of the immune response and provide meaningful insights into COVID-19 immunity according to discrete symptom presentation. |
format | Online Article Text |
id | pubmed-9462709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94627092022-09-10 COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine Huhn, Gregory Poorbaugh, Josh Zhang, Lin Beasley, Stephanie Nirula, Ajay Brothers, Jennifer Welbel, Sharon Wilson, James Gillani, Sheena Weber, Kathleen M. Morack, Ralph Keckler, Kody Benschop, Robert J. PLoS One Research Article BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. METHODS: Cook County Health employees provided blood samples and completed an online survey 8–10 weeks after a PCR-confirmed positive SARS-CoV-2 test (pre-vaccinated, N = 41) and again, 1–4 weeks after completion of a 2-dose series mRNA BNT162b2 COVID-19 vaccine (post-vaccinated, N = 27). Associations were evaluated between SARS-CoV-2 antibody titers, participant demographics, and clinical characteristics. Antibody titers and angiotensin-converting enzyme 2 (ACE2) neutralization were compared before and after the mRNA BNT162b2 COVID-19 vaccine. RESULTS: Antibody titers to the spike protein (ST4), receptor binding domain (RBD), and RBD mutant D614G were significantly associated with anosmia and ageusia, cough, and fever. Spike protein antibody titers and ACE2 neutralization were significantly higher in participants that presented with these symptoms. Antibody titers to the spike protein N-terminal domain (NTD), RBD, and ST4, and ACE2 IC50 were significantly higher in all post-vaccinated participant samples compared to pre-vaccinated participant sample, and not dependent on previously reported symptoms. CONCLUSIONS: Spike protein antibody titers and ACE2 neutralization are associated with the presentation of anosmia and ageusia, cough, and fever after SARS-CoV-2 infection. Symptom response to previous SARS-CoV-2 infection did not influence the antibody response from subsequent vaccination. These results suggest a relationship between infection severity and the magnitude of the immune response and provide meaningful insights into COVID-19 immunity according to discrete symptom presentation. Public Library of Science 2022-09-09 /pmc/articles/PMC9462709/ /pubmed/36083883 http://dx.doi.org/10.1371/journal.pone.0273323 Text en © 2022 Huhn et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Huhn, Gregory Poorbaugh, Josh Zhang, Lin Beasley, Stephanie Nirula, Ajay Brothers, Jennifer Welbel, Sharon Wilson, James Gillani, Sheena Weber, Kathleen M. Morack, Ralph Keckler, Kody Benschop, Robert J. COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title | COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title_full | COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title_fullStr | COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title_full_unstemmed | COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title_short | COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine |
title_sort | covid-19 symptom relationship to antibody response and ace2 neutralization in recovered health systems employees before and after mrna bnt162b2 covid-19 vaccine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462709/ https://www.ncbi.nlm.nih.gov/pubmed/36083883 http://dx.doi.org/10.1371/journal.pone.0273323 |
work_keys_str_mv | AT huhngregory covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT poorbaughjosh covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT zhanglin covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT beasleystephanie covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT nirulaajay covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT brothersjennifer covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT welbelsharon covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT wilsonjames covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT gillanisheena covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT weberkathleenm covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT morackralph covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT kecklerkody covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine AT benschoprobertj covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine |